Navigation Links
The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
Date:5/2/2013

EXTON, Pa., May 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that Janssen/Merck/Mitsubishi Tanabe's Remicade is the market leader for the treatment of ulcerative colitis in the EU5 (France, Germany, Italy, Spain and the United Kingdom), following the approval of its first biologic competitor—another TNF-alpha inhibitor—AbbVie/Eisai's Humira. According to the results of a survey conducted nearly one year after the European approval of Humira for ulcerative colitis, 69 percent of gastroenterologists pointed to Remicade as their most preferred biologic, while 27 percent of respondents indicated Humira.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The TreatmentTrends®: Ulcerative Colitis (EU) report finds that Remicade also leads over Humira in patient share estimates across the major European markets. While the new TNF-alpha inhibitor may not trail far behind Remicade in countries such as the United Kingdom and Germany, gastroenterologists from Italy and France provide estimates half those of Remicade. In addition to the relatively recent approval of Humira, physician perception of Humira's efficacy appears to be a factor limiting uptake as nearly one-third of European gastroenterologists noted its efficacy relative to Remicade as a disadvantage, but less than ten percent stated that its relative efficacy was an advantage. These findings may also explain Remicade's higher patient share compared with Humira in the severe segment (24 percent and 12 percent, respectively) that leads by a wider margin than in the moderate segment (11 percent and 7 percent, respectively).

The findings also reveal that approximately one-third of respondents were aware of new treatments in development for ulcerative colitis. After viewing product profiles of Takeda's vedolizumab, Janssen/Merck/Mitsubishi Tanabe's Simponi and Pfizer's tofacitinib, gastroenterologists reported a mean interest level for tofacitinib that is significantly greater than those of vedolizumab and Simponi. Additionally, tofacitinib received the greatest proportion of gastroenterologists identifying it as offering the most value to their practice. Oral administration was the most common reason given.

"However, when thinking of unmet needs for a new agent for moderate to severe UC, oral administration falls in the middle of the range of importance ratings among surveyed attributes, signaling that this attribute alone will not drive prescribing," said Decision Resources Group Senior Director Joanna Kim , M.Ed. "Efficacy will continue to be a key decision point."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com  


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
2. Allscripts adopts majority voting policy for directors
3. BD Completes Sale of Majority of Discovery Labware Unit
4. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
5. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
6. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
7. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
10. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
11. Local Gastroenterologists First in South Florida to Offer Fecal Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
(Date:6/24/2016)... Knoxville, TN (PRWEB) , ... June 24, 2016 ... ... develop population health management skills and infrastructure. Most providers, however, are unsure how ... Population Health Ascend to define a path forward tailored to an ...
Breaking Medicine News(10 mins):